Trial reportEuropean journal of nuclear medicine and molecular imaging2026
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study.
Trial report in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Irene MariniNuclear Medicine Operative Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Via P. Maroncelli n. 40, Meldola(FC), 47014, Italy.ORCID 0009-0002-6186-688X
Emilio Francesco GiuntaDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy.ORCID 0000-0002-5383-4469
Silvia NicoliniNuclear Medicine Operative Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Via P. Maroncelli n. 40, Meldola(FC), 47014, Italy. silvia.nicolini@irst.emr.it.ORCID 0000-0002-3960-7737
Ilaria GrassiNuclear Medicine Operative Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Via P. Maroncelli n. 40, Meldola(FC), 47014, Italy.ORCID 0000-0002-9566-7670
Flavia FocaBiostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy.ORCID 0000-0002-5529-4769
Anna SarnelliMedical Physics Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy.ORCID 0000-0001-5986-3845
Valentina Di IorioOncological Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy.ORCID 0000-0002-5380-6185
Lilla VizzaBiostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy.ORCID 0009-0002-7734-3426
Erika GianiBiostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy.
Monica CelliNuclear Medicine Operative Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Via P. Maroncelli n. 40, Meldola(FC), 47014, Italy.ORCID 0000-0002-0338-800X
Manuela MontiBiostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy.ORCID 0000-0002-3587-1768
Stefano SeveriNuclear Medicine Operative Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Via P. Maroncelli n. 40, Meldola(FC), 47014, Italy.ORCID 0000-0003-1846-0681
Ugo De GiorgiDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy.ORCID 0000-0001-7520-2908
Francesca BorgiaDepartment of Translational Medicine, University of Ferrara, Via Aldo Moro 8, Ferrara, 44124, Italy.ORCID 0000-0002-9753-9699
Giovanni PaganelliNuclear Medicine Operative Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Via P. Maroncelli n. 40, Meldola(FC), 47014, Italy.ORCID 0000-0002-2631-4652
Federica MatteucciNuclear Medicine Operative Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Via P. Maroncelli n. 40, Meldola(FC), 47014, Italy.ORCID 0000-0001-7455-6253
Maddalena SansoviniNuclear Medicine Operative Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Via P. Maroncelli n. 40, Meldola(FC), 47014, Italy.ORCID 0000-0002-7699-262X
Funding
Ministero della Salute RF-2016-02364230
6 · The paper itself
Abstract
purposeMetastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic challenge. Radioligand therapy (RLT) with
methodsThis prospective, single arm, monocentre, Phase-II study enrolled PSMA-avid mCRPC patients (April 2017-October 2022). Patients received 5.5 GBq of
resultsForty-eight patients were assessed for safety; 44 were evaluable for efficacy. A ≥ 50% PSA decline occurred in 22 patients (50%). At 12 months, PFS was 22.7% (95% CI: 11.8-35.9) and OS 87.9% (95% CI: 73.4-94.8); median OS was 18.8 months. Treatment was generally well tolerated, with mostly Grade 1-2 events. Grade 3 toxicities were rare (6.3%), and no Grade 4 events occurred. One Grade 3 hyponatraemia led to discontinuation.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study. · full record | OpenQuestion